Today: 1 May 2026
Exxon stock jumps after Q4 upstream warning; oil rebound and Jan. 30 earnings loom
9 January 2026
2 mins read

Exxon stock jumps after Q4 upstream warning; oil rebound and Jan. 30 earnings loom

New York, Jan 8, 2026, 19:09 EST — After-hours

  • Exxon shares were last up 3.7% after a filing flagged a potential fourth-quarter upstream earnings hit from weaker crude prices.
  • The company also pointed to a possible lift from stronger refining margins, a key offset investors are watching into results.
  • Traders’ next checkpoints include Friday’s U.S. jobs report and Exxon’s Jan. 30 earnings release.

Exxon Mobil Corp shares jumped 3.7% to $122.91 in after-hours trading on Thursday. This boost came as oil prices bounced back and energy stocks broadly rallied. Investors were also reacting to a company filing released before quarterly earnings.

The update matters because Exxon’s “earnings considerations” snapshot gives one of the first clear glimpses of how the oil giant is shaping up before reporting season, even as estimates fluctuate with every shift in crude prices and fuel margins. These early numbers from the company might influence analysts’ forecasts ahead of management’s Q&A later this month. Reuters

Energy stocks led the S&P 500 sectors on Thursday, while the overall market hardly shifted, ending almost unchanged. Investors are eagerly awaiting Friday’s U.S. employment report, searching for clues on interest rates and the economy. This uneasy environment keeps traders on edge, even when markets barely move.

In its filing, Exxon cautioned that changes in liquids prices could shave off about $0.8 billion to $1.2 billion from its fourth-quarter upstream earnings; upstream means the company’s oil and gas production segment. It also pointed to a possible gas price swing, ranging from a $0.3 billion loss to a modest $0.1 billion gain. On the other side, “industry margins” — a broad label covering refining and chemicals — showed signs of being a possible bright spot for parts of the business. SEC

Analysts expect Exxon to report adjusted earnings of $1.66 per share this quarter, according to LSEG data highlighted in recent reports. “Many brokers… have yet to mark to market,” said Scotiabank analysts, stressing the need to revise forecasts with current commodity prices rather than leaning on outdated figures. WTVB 1590 AM 95.5 FM

Oil prices surged more than 3% on Thursday, hitting their highest levels in two weeks. Brent crude closed at $61.99 a barrel, while U.S. WTI ended the day at $57.76. Traders faced a tangle of events: unrest in Venezuela paired with supply jitters tied to Russia, Iraq, and Iran. Raymond James strategist Pavel Molchanov cautioned that Iranian oil exports “could be at risk” depending on how the situation develops. Reuters

Peers have begun dropping early clues. Take Shell, for example: it posted a loss in its chemicals and products division for the fourth quarter and said oil trading results were “significantly” weaker than the prior quarter. This prompted analysts to slash their forecasts and question how fast buybacks can materialize. Reuters

Exxon, meanwhile, cautioned that this snapshot isn’t meant as an earnings forecast and leaves out many factors like operating performance, unexpected shutdowns, or currency swings. The company also highlighted potential “identified items” such as impairments and restructuring charges — those line items that can swing reported profits even if core operations remain steady. Exxon Mobil Corporation

Investors will be watching closely to see if crude holds steady as Friday’s session approaches. Meanwhile, the upcoming payrolls report might jolt rate expectations. Exxon said it plans to release its fourth-quarter results around 5:30 a.m. CT on Friday, Jan. 30.

Stock Market Today

  • Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK
    May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines and capital strategies amid challenging market conditions.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 01.05.2026

1 May 2026
LIVEMarkets rolling coverageStarted: May 1, 2026, 12:00 AM EDTUpdated: May 1, 2026, 12:13 AM EDT Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines
Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Robinhood stock slips after CEO share sale; jobs report and Feb. 10 earnings set the next test
Previous Story

Robinhood stock slips after CEO share sale; jobs report and Feb. 10 earnings set the next test

Visa stock slips as Visa Direct deal hits tape; jobs data now the swing factor
Next Story

Visa stock slips as Visa Direct deal hits tape; jobs data now the swing factor

Go toTop